Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Financing Activities (2020 - 2024)

Immuneering has reported Cash from Financing Activities over the past 5 years, most recently at -$40988.0 for Q4 2024.

  • Quarterly results put Cash from Financing Activities at -$40988.0 for Q4 2024, down 623.14% from a year ago — trailing twelve months through Dec 2024 was $5.3 million (down 81.35% YoY), and the annual figure for FY2025 was $226.6 million, up 4172.32%.
  • Cash from Financing Activities for Q4 2024 was -$40988.0 at Immuneering, down from $4.4 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for IMRX hit a ceiling of $118.5 million in Q3 2021 and a floor of -$184677.0 in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $110447.5 (2022), compared with a mean of $13.5 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 2556.14% in 2022 and later skyrocketed 101297.86% in 2023.
  • Immuneering's Cash from Financing Activities stood at $37.0 million in 2020, then plummeted by 99.98% to $7519.0 in 2021, then tumbled by 2556.14% to -$184677.0 in 2022, then surged by 104.24% to $7835.0 in 2023, then crashed by 623.14% to -$40988.0 in 2024.
  • The last three reported values for Cash from Financing Activities were -$40988.0 (Q4 2024), $4.4 million (Q3 2024), and $979923.0 (Q1 2024) per Business Quant data.